OB/GYN and Women's Health

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jacqueline Wong, MD, MSCR, FACOG For patients with endometriosis, treatment delays can profoundly impact both quality of life and clinical outcomes. Proactive strategies that address logistical barriers—such as prior authorizations—combined with education and multidisciplinary support are essential in improving care. Join Dr. Charles Turck and Dr. Jacqueline Wong as they explore practical approaches for managing this complex condition and navigating potential hurdles. Dr. Wong is a minimally invasive gynecologic surgeon and an Assistant Professor of Obstetrics and Gynecology in the School of Medicine at Oregon Health and Science University in Portland.

Host: Jennifer Caudle, DO Guest: Johanna Finkle, MD, FACOG As GLP-1 therapies grow in popularity for weight management and diabetes, an unexpected consequence has emerged: a rise in unplanned pregnancies due to reduced oral contraceptive effectiveness. Dr. Jennifer Caudle sits down with Dr. Johanna Finkle, a weight loss specialist and OB/GYN at the University of Kansas Health System, to explore the mechanisms behind this trend and outline practical, long-acting contraceptive alternatives that maintain efficacy during GLP-1 use.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there’s a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it’s also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it’s important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to share her insights on PI3Kα testing and targeted therapies for HR+/HER2- advanced breast cancer is Dr. Hope Rugo, Director of the Women's Cancers Program, Division Chief of Breast Medical Oncology and Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.

Guest: Brian Slomovitz, MD Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that could redefine treatment pathways for patients with advanced or recurrent disease. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Host: Ashley Baker, MSN, PMHNP Guest: Giancarlo Moscol, M.D. Metastatic breast cancer treatment isn't one-size-fits-all. Providers must carefully balance clinical outcomes, toxicity, and patient lifestyle and preferences. Dr. Giancarlo Moscol joins Ms. Ashley Baker to outline a structured, three-tiered decision-making process that weighs treatment efficacy, side effect burden, and real-world logistics like administration route and patient support systems. Dr. Moscol is an Associate Professor in teh Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston.

Host: Ashley Baker, MSN, PMHNP Guest: Giancarlo Moscol, M.D. Effective treatment sequencing in patients with metastatic breast cancer is critical for maximizing clinical benefit and maintaining quality of life. Ms. Ashley Baker sits down with Dr. Giancarlo Moscol to discuss how to approach sequencing decisions based on tumor biology, disease progression patterns, and actionable mutations. Dr. Moscol is an Associate Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston.

Host: Marlene Mimi Maeusli, PhD. New insights from DESTINY-Breast04 highlight how trastuzumab deruxtecan (T-DXd) not only extends survival but also delays symptom deterioration in HER2-low metastatic breast cancer. In this AudioAbstract, Dr. Mimi Maeusli discusses key takeaways from the outcomes analysis and what they mean for treatment planning and patient-centered care.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Whitney Trotter Ross, MD, MSCI Despite advances in endometriosis treatment, bias and stigma continue to delay diagnosis and disrupt care for many patients. Informed, empathetic care is key for supporting diverse patient populations. Dr. Charles Turck sits down with Dr. Whitney Ross to unpack how historical misconceptions still influence prescribing habits and discuss actionable strategies for counseling, selecting a treatment plan, and building trust. Dr. Ross is an Assistant Professor of Obstetrics and Gynecology in the Division of Minimally Invasive Gynecologic Surgery at Washington University in St. Louis.

Guest: Tamatha Fenster, M.D., M.S. Tamatha Fenster, M.D., M.S., gynecologic surgeon at NewYork-Presbyterian and director of innovation and technology at The Weill Cornell Medicine Fibroid and Adenomyosis Center, explains how her team has developed a new 3D MRI technology to enhance patient outcomes in fibroid surgery. The novel software, called smartHER MRI, renders a 3D image of a patient’s uterus to more accurately identify fibroids and their precise location, which can be used for both laparoscopic and robotic surgical procedures. In a pilot study analyzing smartHER MRI vs. 2D imaging, results demonstrated that surgeons who relied on traditional imaging had residual fibroids at the 6-month follow-up, while surgeons who used smartHER MRI had no residual fibroids with their patients. © 2025 NewYork-Presbyterian

Host: Brian P. McDonough, MD, FAAFP Guest: Hugh S. Taylor, MD Endometriosis care is often delayed due to diagnostic and treatment access challenges—but early recognition and proactive strategies can change that. In this expert-led discussion, Dr. Brian McDonough sits down with Dr. Hugh Taylor to explore how we can clinically diagnose endometriosis without relying on surgery, streamline prior authorizations, and guide patients toward affordable treatment options while empowering patients through advocacy and education. Dr. Taylor is the Anita O’Keeffe Young Professor and Chair of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP In addition to heavy menstrual bleeding, patients with uterine fibroids often deal with many other considerable effects on their physical and mental wellbeing. To provide optimal care, it’s important to recognize the full impact of fibroids, communicate carefully about treatment options, and promote equitable access to care. Dr. Charles Turck sits down with Dr. Ayman Al-Hendy to learn more about how we can address the multifaceted burden of uterine fibroids. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Joseph E. Patruno, MD From delayed diagnosis to chronic pain and fertility issues, endometriosis presents a range of challenges that require individualized attention. By focusing on each patient’s unique symptoms and priorities, we can better tailor care and improve outcomes. Join Dr. Mary Katherine Cheeley as she speaks with Dr. Joseph Patruno, an OB/GYN at Lehigh Valley Jefferson Health Network, about practical strategies for delivering comprehensive, patient-centered care.

Guest: Riley Bove, MD, MMSc From pregnancy planning and postpartum relapse risk to the overlapping symptoms of menopause, women with multiple sclerosis (MS) face unique challenges throughout the reproductive lifespan. Here to share key takeaways from her session at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting that focused on how we can better care for these patients is Dr. Riley Bove, a practicing neurologist and clinician scientist in the UCSF Weill Institute for Neurosciences.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Despite longstanding reliance on surgery, recent advancements have reshaped our approach to uterine fibroids. However, common myths and misconceptions have limited the adoption of newer therapies, leaving many patients unaware of their available options. Join Dr. Charles Turck and Dr. Ayman Al-Hendy as they explain shifting treatment paradigms and patient education strategies in uterine fibroid care. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Guest: Megan Kruse, MD When treating patients with metastatic breast cancer, effective communication and patient support are key. Join Dr. Megan Kruse, a medical oncologist at Cleveland Clinic in Ohio, as she explains how to align treatment goals with patient values, address physical and emotional needs through multidisciplinary support, and incorporate integrative medicine approaches.

Host: Megan Kruse, MD When treating patients with HER2-positive metastatic breast cancer, understanding how to monitor and manage potential side effects is essential for optimal care. Join Dr. Megan Kruse, a medical oncologist at Cleveland Clinic in Ohio, as she explains key considerations for managing side effects from tucatinib and trastuzumab deruxtecan.

Guest: Fernando López-Ríos, MD, PhD Guest: Christian Rolfo, MD, PhD Guest: Prof. Charlie Gourley In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers. Topics of conversation include the following: Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer. The full programme is also featured on the COR2ED website, here: HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

Guest: Sara Horst, MD, MPH, FACG While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it’s still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.